CoChat

A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania

Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., Baldessarini, R. J. · 2015 · Psychological Medicine

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.

Abstract

Background: Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments. Method: We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania. Results: Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges’ g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v . aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers. Conclusions: Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.

Overview

Integrity signals

Registry

Crossref · 10.1017/s0033291714001305

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 72 references

Research works printed but not linked: 3

  1. Kriston, Bipolar Book: History, Neurobiology, and Treatment
  2. Lerer, 1987, Carbamazepine vs. lithium in mania: double-blind study, Journal of Clinical Psychiatry, 48, 89
  3. Ortega Soto, 1993, Carbamazepine vs haloperidol in treatment of manic episodes: controlled clinical trial, (Spanish) Salud Mental, 16, 44

Cited by

See all 134

Metadata

Authors
Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J.
Affiliations
  • AGH University of Krakow (PL)
  • Massachusetts General Hospital (US)
  • Zucker Hillside Hospital (US)
  • Harvard University (US)
Venue
Psychological Medicine
Published
2014-07-18
Volume
45
Issue
2
Pages
299-317
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2162319254
Cited by
128
References
73
Citations by year
2026: 4 · 2025: 6 · 2024: 12 · 2023: 9 · 2022: 25 · 2021: 14 · 2020: 14 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 10 · 2014: 1
FWCI
7.12
Type
journal article
Language
en
Open access
closed
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar mania, antimanic drugs, bipolar I disorder, antipsychotic drugs, mood stabilizers, atypical antipsychotics, valproic acid, risperidone, aripiprazole, olanzapine, quetiapine, haloperidol, treatment discontinuation, treatment efficacy
MeSH terms
Bayes Theorem, Bipolar Disorder, Humans, Patient Dropouts, Randomized Controlled Trials as Topic, Treatment Outcome, Antimanic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. https://app.cochat.ai/papers/10.1017/s0033291714001305
The paper
Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J. (2015). A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychological Medicine. https://doi.org/10.1017/s0033291714001305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.